Clinical Trials Browser

Phase 1/2 × Prostatic Neoplasms, Castration-Resistant × sacituzumab govitecan × Clear all

NCT04381832 2025-07-22

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Phase 1/2 Completed

Prostatic Neoplasms, Castration-Resistant